Vanguard Global Advisers’s Atara Biotherapeutics ATRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$39.6K Buy
4,654
+3,198
+220% +$29K ﹤0.01% 3142
2026
Q2
$16.7K Hold
1,456
– – ﹤0.01% 3378
2026
Q1
$6.89K Hold
1,456
– – ﹤0.01% 3526

Other funds holding ATRA

Vanguard Global Advisers's ATRA Position: Q3 2026 in Review

Vanguard Global Advisers increased its Atara Biotherapeutics (ATRA) stake by 220% in Q3 2026, buying an estimated $29K and bringing the position to 4,654 shares worth $39.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3142.

Vanguard Global Advisers first reported a position in ATRA in Q1 2026 and has held it in 3 quarters since. 36 funds tracked by Wall St. Rank hold ATRA as of Q3 2026.

  • Vanguard Global Advisers held 4,654 shares of Atara Biotherapeutics worth $39.6K as of Q3 2026.
  • Vanguard Global Advisers bought 3,198 Atara Biotherapeutics shares in Q3 2026, an estimated $29K.
  • Atara Biotherapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #3142 holding.
  • Vanguard Global Advisers first reported a position in Atara Biotherapeutics in Q1 2026 and has held it in 3 quarters since.
  • 36 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.